Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kathryn Anastassopoulos"'
Autor:
Neel Shah, Fulton F. Velez, Samuel Colman, Laura Kauffman, Charles Ruetsch, Kathryn Anastassopoulos, Yuri Maricich
Publikováno v:
Advances in Therapy. 39:4146-4156
Autor:
Charles Ruetsch, Sam Colman, Kathryn Anastassopoulos, Laura Kauffman, Yuri A. Maricich, Fulton Velez
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Fulton F Velez,1 Sam Colman,2 Laura Kauffman,2 Charles Ruetsch,3 Kathryn Anastassopoulos,2 Yuri A Maricich1 1Pear Therapeutics, Inc., Boston, MA, USA; 2Covance Market Access, Gaithersburg, MD, USA; 3Health Analytics, Columbia, MD, USACorrespondence:
Autor:
Joseph C. Cappelleri, Kathryn Anastassopoulos, Laura Kauffman, Michael Benigno, Elena Peeva, Jennifer Lapthorn, Arash Mostaghimi, Linda H. Chen, Peter M Wahl, Margarita Udall, Shoshana R Daniel, Pratibha Chander
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology. 13:259-266
Purpose Alopecia areata (AA) is an autoimmune disease characterized by the development of non-scarring alopecia. The prevalence is not well known, and estimates vary considerably with no recent estimates in the United States (US). The objective of th
Autor:
Khaled Ezzedine, Rebecca Baik, Vanja Sikirica, Yuji Yamaguchi, Kavita Gandhi, Amit G. Pandya, Reema Patel, Kathryn Anastassopoulos, Lynne Napatalung, Shoshana R Daniel
Publikováno v:
JAMA Dermatology
This survey study aims to estimate the point prevalence of vitiligo among US adults aged 18 to 85 years.
Key Points Question What is the current point prevalence of vitiligo among adults in the US? Findings This cross-sectional, population-based
Key Points Question What is the current point prevalence of vitiligo among adults in the US? Findings This cross-sectional, population-based
Autor:
Laura Kauffman, Sean M. Murphy, Fulton Velez, Sam Colman, Kathryn Anastassopoulos, Yuri A. Maricich
Publikováno v:
Hospital practice (1995). 49(5)
Outcomes associated with buprenorphine therapy for the treatment of opioid use disorder (OUD) are suboptimal. reSET-O is an FDA-authorized prescription digital therapeutic (PDT) delivering neurobehavioral therapy via mobile devices to patients with O
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 21(1)
Buprenorphine medication assisted treatment (B-MAT) adherence for opioid use disorder (OUD) is suboptimal. reSET-O, an FDA-cleared prescription digital therapeutic, delivers neurobehavioral therapy (community-reinforcement approach+fluency training+c
Publikováno v:
Epilepsybehavior : EB. 92
While antiepileptic drug (AED) treatment effectiveness is traditionally assessed based on seizure frequency reduction (SFR), the overall value of AEDs in managing epilepsy and associated sequelae may be best assessed by how patients feel and function
Autor:
Sam Colman, Kathryn Anastassopoulos, D. Mehta, G Rhys Williams, Joyce A. Cramer, Todd Grinnell
Publikováno v:
Epilepsy & Behavior. 112:107312
The relationships between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life (HRQoL) may be important for determining the overall impact of medication therapy on patients with epileps
Autor:
David Blum, Luigi Maria Specchio, T. Christopher Bond, Xuezhe Wang, Joana Moreira, Fulton Velez, Frank Gilliam, Kathryn Anastassopoulos, F. Rocha, Joyce A. Cramer, Philippe Ryvlin
Publikováno v:
Epilepsy & Behavior. 53:149-153
The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures.The Seizure Severity Questionnaire (SSQ) was adminis
Autor:
John Niewoehner, Li Wang, Michael Philbin, Tyler Knight, Breanna Popelar, T. Christopher Bond, Kathryn Anastassopoulos
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Tyler Knight,1 T Christopher Bond,1 Breanna Popelar,2 Li Wang,3 John W Niewoehner,4 Kathryn Anastassopoulos,1 Michael Philbin4 1Covance Market Access Services Inc., Gaithersburg, MD, 2Xcenda, LLC, Palm Harbor, FL, 3STATinMED Research, Ann Arbor, MI,